Spots Global Cancer Trial Database for Letrozole as a Treatment of Endometrial Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Letrozole as a Treatment of Endometrial Cancer
Official Title: Predicting Aromatase Inhibitor Responsiveness in Endometrial Carcinoma
Study ID: NCT00997373
Conditions
Interventions
Study Description
Brief Summary: Some cases of endometrial cancer are dependent on estrogen for their growth. Letrozole blocks estrogen production in the body. The purpose of this study is to determine if the investigators can predict which patients might benefit from Letrozole treatment by studying the many different forms of the estrogen receptor molecule that exist within the cancer tissues. To participate in this study, the patients must be 40 years of age or older and have biopsy-proven endometrial carcinoma, either well differentiated or moderately differentiated forms. Also, to be eligible to participate in this study, the patients need to be healthy enough to have a hysterectomy. If the patients are less than age 60, they will need a blood test (FSH) to confirm that they have gone into menopause.
Detailed Description:
Eligibility
Minimum Age: 40 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
University of California Davis, Sacramento, California, United States
University of California, Davis, Sacramento, California, United States
Contact Details
Name: Lloyd H. Smith, MD, PhD
Affiliation: University of California, Davis
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
